Whitepaper: European Biotech Act – Regulatory impact and implications for sponsors

This whitepaper provides a clear and concise overview of the Act’s background, intent, and the key pieces of regulatory legislation it is set to influence. It looks into critical areas such as clinical trials and Supplementary Protection Certificate (SPC) extensions, highlighting the improvements expected to accelerate biotech innovation and streamline development pathways across the EU.

Beyond policy, the paper translates these changes into practical implications for sponsors. From regulatory affairs and quality assurance to supply chain, technical operations, and launch readiness, it outlines what organisations need to consider to remain compliant and competitive. It also examines how the evolving landscape will impact EU market strategy and territory expansion, helping companies position themselves effectively in a rapidly shifting environment.

The paper is a collaboration between Arex Advisor and Supply Chain Operations.